What's Happening?
Amylyx Pharmaceuticals has announced the initiation of a U.S. Expanded Access Program (EAP) for adults suffering from post-bariatric hypoglycemia (PBH) following Roux-en-Y gastric bypass surgery. This
program provides access to avexitide, an investigational glucagon-like peptide-1 receptor antagonist, for up to 250 eligible patients. The EAP is designed for individuals with serious unmet medical needs who cannot participate in ongoing clinical trials and have exhausted other management options. Avexitide is currently being evaluated in the Phase 3 LUCIDITY clinical trial, with results expected in the third quarter of 2026. The trial aims to assess the efficacy and safety of avexitide in reducing hypoglycemic events in PBH patients.
Why It's Important?
The Expanded Access Program is significant as it addresses the unmet medical needs of PBH patients, a condition affecting approximately 8% of individuals who have undergone bariatric surgery in the U.S. PBH can lead to severe hypoglycemic events, impacting patients' quality of life and safety. Avexitide, if successful, could become the first FDA-approved therapy for PBH, offering a new treatment option for this debilitating condition. The program reflects Amylyx Pharmaceuticals' commitment to advancing treatment options for conditions with high unmet needs, potentially improving patient outcomes and reducing healthcare burdens associated with PBH.
What's Next?
The Phase 3 LUCIDITY trial is ongoing, with topline data expected in Q3 2026. If the trial results are favorable, Amylyx Pharmaceuticals plans to pursue FDA approval for avexitide, with a commercial launch anticipated in 2027. The success of avexitide could pave the way for further research and development in treating hypoglycemic conditions, potentially expanding its use to other related disorders. Stakeholders, including healthcare providers and patients, are likely to closely monitor the trial outcomes and subsequent regulatory decisions.
